Davide Campari-Milano

Q2 FY24 – Campari has caught the flu

01/08/24 -"Although Campari’s results have been relatively resilient against a backdrop of soft market dynamics, the lack of sunshine leading to a negative mix is weighing on the Italian company. ..."

PDF page sample
Pages
56
Language
English
Published on
01/08/24
Download
You may also be interested by these reports :
18/09/25
We have revised our model to reflect the increase in sugar inventories in Brazil during August, which came in above expectations and is driving ...
02/09/25
Autumn approaches (again) and Nestlé changes the CEO once more
01/09/25
We have updated our DCF valuation to reflect slightly stronger than expected FY24/25 EBITDA of USD 7,422m (+15% vs. forecast), resulting in modest ...
28/08/25
Pernod Ricard reported stronger-than-expected profits despite an organic decline in recurring operations. Challenges are anticipated in H1 26, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO